Purpose: Chromosomal instability (CIN) is a common phenomenon in colorectal cancer, but its role and underlying cause remain unknown. We have identified that mitotic regulator microtubule-associated protein 9 (MAP9) is a critical regulator of CIN in colorectal cancer. We thus studied the effect of MAP9 loss on colorectal cancer in Map9-knockout mice and in cell lines. Experimental Design: We generated colon epithelial–specific Map9-knockout mice and evaluated colorectal cancer development. Effect of Map9 knockout on colorectal cancer progression was determined in chemical or ApcMin/þ-induced colorectal cancer. Molecular mechanism of MAP9 was determined using spectral karyotyping, microtubule assays, and whole-genome sequencing (WGS). Clinical significance of MAP9 was examined in 141 patients with CRC. Results: Spontaneous colonic tumors (9.1%) were developed in colon epithelium–specific Map9-knockout mice at 17 months, but none was observed in wild-type littermates. Map9 deletion accelerated colorectal cancer formation both in ApcMin/þ mice and azoxymethane-treated mice, and reduced survival in ApcMin/þ mice. Mechanistically, MAP9 stabilized microtubules and mediated mitotic spindle assembly. MAP9 also maintained the spindle pole integrity and protected K-fiber from depolymerization at spindle poles. MAP9 loss induced severe mitosis failure, chromosome segregation errors, and aneuploidy, leading to transformation of normal colon epithelial cells. WGS confirmed enhanced CIN in intestinal tumors from Map9 knockout ApcMin/þ mice. In patients with colorectal cancer, MAP9 was frequently silenced and its downregulation was associated with poor survival. Conclusions: MAP9 is a microtubule stabilizer that contributes to spindle stability and inhibits colorectal tumorigenesis, supporting the role of MAP9 as a tumor suppressor for preventing CIN in colorectal cancer.
|Number of pages||12|
|Journal||Clinical Cancer Research|
|State||Published - Feb 1 2020|
Bibliographical noteFunding Information:
This study was supported by HMRF Hong Kong (03140856), National Key R&D Program of China (2017YFE0190700), Science and Technology Program Grant Shenzhen (JCYJ20170413161534162), Science and Technology Program Grant Shenzhen (JCYJ20170413161534162), RGC-GRF Hong Kong (14111216, 14163817), Vice-Chancellor's Discretionary Fund CUHK, CUHK direct grant, and Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.
© 2019 American Association for Cancer Research.
ASJC Scopus subject areas
- Medicine (all)